

CMS Announces First Selected Drugs for Medicare Price Negotiation

- On August 29, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 Part D drugs selected for negotiation under the Medicare Drug Price Negotiation Program. The negotiation process for these drugs will take place during 2023 and 2024, and maximum fair prices will be applicable starting in 2026. The selected drugs are:
 - Eliquis
 - Jardiance
 - Xarelto
 - Januvia
 - Farxiga
 - Entresto
 - Enbrel
 - Imbruvica
 - Stelara
 - Fiasp
- The primary manufacturers of the drugs announced today will have until October 1, 2023, to choose whether to sign agreements to begin the negotiation process for 2026.
- CMS will collect information on selected drugs from primary manufacturers and members of the public throughout Fall 2023.
 - Primary manufacturers must submit manufacturer-specific data on selected drugs by October 2, 2023. All members of the public may submit information related to therapeutic alternatives, unmet medical need, and impact on specific populations of the selected drug by this same deadline.
 - CMS will hold patient-focused listening sessions between October 30, 2023, and November 15, 2023, and invite primary manufacturers of each selected drug to meet to discuss its data submission.
- By February 1, 2024, CMS will send an initial offer of a maximum fair price for a selected drug with a justification to each participating manufacturer. Manufacturers

will have an opportunity to provide a counteroffer and CMS respond to the counteroffer over the next six months. The negotiation period will end on August 1, 2024.

- By September 1, 2024, CMS will publish the maximum fair prices that have been negotiated for drugs selected for negotiation for 2026.

More on This Topic:

- [CMS Press Release](#)
- [Fact Sheet](#)
- [Implementation Timeline](#)

For questions, please reach out to [Vicky Jucelin](#).

AMCP | 675 North Washington Street, Suite 220 | Alexandria, VA, 22314

[Manage Preferences](#)

